Pharmaceuticals company Adcock Ingram expects its earnings per share (EPS) for the six-month period to December 31, 2016, to be at least 60% higher than the comparative period of 2015.
The company noted that the 60c-a-share increase from the EPS of 99.6c reported in the prior year came on the back of certain nonrecurring capital profits, including the disposal of the group’s business in India.
Further, Adcock expects its headline earnings a share to be at least 40% higher than the 99.8c reported in the previous corresponding period.